Our Pricing

What Results Can You Expect?

Published on: June 03, 2026

Understanding weight loss results UK prescription medications can deliver helps set realistic expectations before starting treatment. At Cured Pharmacy, our UK-registered clinical team guides patients through evidence-based weight loss programmes using licensed medications like Mounjaro, Wegovy, and Saxenda, with transparent pricing and ongoing support throughout your journey.

Clinical Trial Results: What the Evidence Shows

The most robust data on weight loss results comes from large-scale clinical trials conducted across multiple countries, including the UK. Tirzepatide (Mounjaro) demonstrated the highest average weight reduction in the SURMOUNT-1 trial, with participants losing an average of 22.5% of their initial body weight over 72 weeks on the 15mg dose [1]. This translates to approximately 24kg for someone starting at 105kg.

Semaglutide-based treatments also show substantial results. In the STEP-1 trial, participants using once-weekly injectable semaglutide (Wegovy) achieved an average 14.9% body weight reduction over 68 weeks [2]. Daily liraglutide (Saxenda) produced an average 8% weight loss over 56 weeks in the SCALE trial [3]. These figures represent averages — individual results vary based on adherence, lifestyle modifications, and metabolic factors.

It's important to note that all participants in these trials followed reduced-calorie diets and increased physical activity alongside medication. Prescription weight loss treatments work by reducing appetite and improving satiety, but they amplify — rather than replace — healthy lifestyle changes [1][2][3].

Timeline: When Will You See Weight Loss Results?

Most patients notice reduced appetite within the first week of starting GLP-1 receptor agonist treatments like Mounjaro, Wegovy, or Saxenda. However, visible weight loss typically becomes apparent after 4-8 weeks of consistent use, once your body has adjusted to the medication and you've established new eating patterns.

Weight loss accelerates during months 2-6 as doses are gradually increased according to your prescriber's titration schedule. The majority of total weight reduction occurs within the first 12 months of treatment, with results plateauing thereafter as your body reaches a new metabolic equilibrium [1][2]. Continuing treatment helps maintain these results long-term, whilst discontinuation often leads to gradual weight regain.

Factors That Influence Your Timeline

Your individual timeline depends on several variables: starting BMI, adherence to dosing schedules, dietary changes, physical activity levels, and underlying metabolic conditions. Patients with higher starting weights often see more rapid initial losses, whilst those closer to their target weight may experience slower but steady progress. Your UK prescriber will monitor your response and adjust treatment accordingly.

Mounjaro Weight Loss Results: The Dual-Action Advantage

Mounjaro (tirzepatide) represents a significant advancement in weight management as the first dual GIP/GLP-1 receptor agonist licensed in the UK by the MHRA. By activating two complementary hormone pathways rather than one, tirzepatide produces superior weight loss results compared to single-pathway medications in head-to-head trials [4].

In the SURPASS-2 trial, which directly compared tirzepatide to semaglutide, participants on the highest tirzepatide dose lost an average of 5.5kg more than those on semaglutide 1mg over 40 weeks [4]. Starting from £135.00 at Cured Pharmacy, Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen, with doses gradually increased from 2.5mg to a maintenance dose of 5mg, 10mg, or 15mg based on individual response and tolerability.

Real-world UK patient experiences mirror clinical trial findings. Our prescribers report that patients typically lose 1-2kg per week during the active weight loss phase, with most achieving 15-20% total body weight reduction within 9-12 months when combined with dietary modifications and regular physical activity [1][4].

Who Achieves the Best Results with Mounjaro?

Clinical data suggests that patients with BMI over 30 (or over 27 with weight-related comorbidities) who maintain consistent weekly dosing and follow a structured nutrition plan achieve optimal outcomes. Those with type 2 diabetes often experience the additional benefit of improved glycaemic control alongside weight reduction. Your UK prescriber will assess your suitability during your free online consultation.

Wegovy and Saxenda: Proven Semaglutide and Liraglutide Results

Wegovy (semaglutide) has established itself as a highly effective weight loss treatment since receiving UK licensure. The STEP trial programme demonstrated that 86% of participants achieved at least 5% weight loss, whilst 69% achieved at least 10% reduction — thresholds associated with significant health improvements including reduced cardiovascular risk and improved metabolic markers [2].

Saxenda (liraglutide) offers an alternative for patients who prefer daily injections or have contraindications to newer medications. Though producing more modest average weight loss of 8% over 56 weeks, Saxenda remains a valuable option with an established safety profile spanning over a decade of clinical use [3]. Available from £135.00 at Cured Pharmacy, it's often considered for patients new to injectable weight loss treatments.

Both medications require gradual dose escalation to minimise gastrointestinal side effects. Your prescriber will provide a detailed titration schedule, typically increasing doses every 4 weeks until reaching the therapeutic maintenance dose. Adherence to this schedule is crucial for achieving optimal weight loss results whilst managing tolerability.

Non-Injectable Options: Orlistat and Oral Semaglutide Results

For patients who prefer not to use injections, oral medications provide alternative pathways to weight loss. Orlistat (available as prescription-strength Xenical or lower-dose Alli and Orlos) works by blocking approximately 30% of dietary fat absorption in the intestines. Clinical trials show an average 5-10% weight loss over 12 months when combined with a reduced-calorie, lower-fat diet [5].

Wegovy Oral Tablets represent the newest addition to UK weight loss treatments, offering the benefits of semaglutide in a daily pill format. Early clinical data suggests comparable efficacy to injectable semaglutide, with the convenience of oral administration appealing to needle-averse patients. Available from £135.00 at Cured Pharmacy, oral semaglutide requires specific timing relative to meals for optimal absorption.

The choice between injectable and oral treatments depends on your preferences, lifestyle, and clinical profile. Injectable GLP-1 medications generally produce greater average weight loss, whilst oral options offer convenience and may suit those with needle phobia or specific medical considerations. Your UK prescriber will discuss the most appropriate option during your consultation.

Maximising Results with Orlistat

Orlistat requires strict adherence to a lower-fat diet (typically under 30% of calories from fat) to minimise gastrointestinal side effects and maximise efficacy. Patients who carefully monitor their fat intake and take the medication with each main meal achieve the best results, with some studies showing up to 10% total body weight reduction over 12 months [5].

Maintaining Your Weight Loss Results Long-Term

Achieving initial weight loss is only the first phase of successful treatment — maintaining those results requires ongoing commitment and often continued medication. Clinical trials consistently show that discontinuing GLP-1 medications leads to gradual weight regain, with participants regaining approximately two-thirds of lost weight within one year of stopping treatment [6].

Long-term maintenance strategies include continuing your prescribed medication at the maintenance dose, establishing sustainable dietary patterns rather than restrictive diets, incorporating regular physical activity (aim for 150-300 minutes of moderate-intensity exercise weekly), and attending regular follow-up consultations with your prescriber to monitor progress and adjust treatment as needed.

At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout your weight loss journey. We offer repeat prescription services with regular reviews to ensure your treatment remains appropriate, effective, and safe. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to maintain the highest standards of pharmaceutical care.

When to Consider Adjusting Your Treatment

If weight loss plateaus for more than 8-12 weeks despite adherence to medication and lifestyle modifications, your prescriber may recommend adjusting your dose, switching to a different medication, or investigating potential underlying factors such as thyroid dysfunction or medication interactions. Regular monitoring ensures you receive optimal treatment tailored to your evolving needs.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. Clinical guideline [CG189]. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual weight loss results vary based on adherence, lifestyle factors, and medical history. Past clinical trial results do not guarantee individual outcomes.